Polydex Pharmaceuticals Valuation
| POLXFDelisted Stock | USD 1.99 0.00 0.00% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Polydex Pharmaceuticals holds a recent Real Value of $1.62 per share. The prevailing price of the company is $1.99. Our model determines the value of Polydex Pharmaceuticals from analyzing the company fundamentals such as Shares Outstanding of 3.43 M, return on equity of -0.18, and Operating Margin of (0.22) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors support locking in undervalued entities and disposing overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Polydex Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Polydex Pharmaceuticals is based on 3 months time horizon. Increasing Polydex Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Polydex Pharmaceuticals is useful when determining the fair value of the Polydex pink sheet, which is usually determined by what a typical buyer is willing to pay for full or partial control of Polydex Pharmaceuticals. Since Polydex Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Polydex Pink Sheet. However, Polydex Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.99 | Real 1.62 | Hype 1.99 |
The real value of Polydex Pink Sheet, also known as its intrinsic value, is the underlying worth of Polydex Pharmaceuticals Company, which is reflected in its stock price. It is based on Polydex Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Polydex Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Polydex Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Polydex Pharmaceuticals helps investors to forecast how Polydex pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Polydex Pharmaceuticals more accurately as focusing exclusively on Polydex Pharmaceuticals' fundamentals will not take into account other important factors: Polydex Pharmaceuticals Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Polydex Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Polydex Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Polydex Pharmaceuticals competition to find correlations between indicators driving Polydex Pharmaceuticals's intrinsic value. More Info.Polydex Pharmaceuticals is considered to be number one stock in price to earning category among related companies. It is considered to be number one stock in price to book category among related companies fabricating about 0.03 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Polydex Pharmaceuticals is roughly 29.50 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Polydex Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Polydex Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Polydex Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Polydex Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Polydex Pharmaceuticals and how it compares across the competition.
About Polydex Pharmaceuticals Valuation
The pink sheet valuation mechanism determines the current worth of Polydex Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Polydex Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Polydex Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Polydex Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Polydex Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Polydex Pharmaceuticals. We calculate exposure to Polydex Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Polydex Pharmaceuticals's related companies.Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada. Polydex Pharm operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 21 people.
8 Steps to conduct Polydex Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Polydex Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Polydex Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Polydex Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Polydex Pharmaceuticals' revenue streams: Identify Polydex Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Polydex Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Polydex Pharmaceuticals' growth potential: Evaluate Polydex Pharmaceuticals' management, business model, and growth potential.
- Determine Polydex Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Polydex Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Polydex Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Polydex Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Quarterly Earnings Growth Y O Y | -0.374 | |
| Retained Earnings | -18.1 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Polydex Pink Sheet
If you are still planning to invest in Polydex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Polydex Pharmaceuticals' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |